Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition

The combination of immune checkpoint inhibitors (ICIs) and other anticancer agents is the standard of care for various cancers. Bevacizumab, an anti-angiogenesis inhibitor, causes serious adverse events such as pulmonary hemorrhage (PH). Here, we present a case of drug-induced diffuse alveolar hemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Shijubou, Naoki, Sawai, Takeyuki, Hatakeyama, Taku, Munakata, Satoru, Yamazoe, Masami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012575/
https://www.ncbi.nlm.nih.gov/pubmed/35449623
http://dx.doi.org/10.7759/cureus.23272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012575/
https://www.ncbi.nlm.nih.gov/pubmed/35449623
http://dx.doi.org/10.7759/cureus.23272

Ejemplares similares